Research progress of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease
10.3760/cma.j.cn441217-20241119-01134
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂在慢性肾脏病中的研究进展
- Author:
Qianling LIU
1
;
Wei CHEN
1
Author Information
1. 中山大学附属第一医院肾内科，广东省肾脏病重点实验室，广州 510080
- Publication Type:Journal Article
- Keywords:
Sodium-glucose transporter 2 inhibitors;
Kidney diseases;
Therapy
- From:
Chinese Journal of Nephrology
2025;41(4):285-289
- CountryChina
- Language:Chinese
-
Abstract:
The research advancements of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in chronic kidney disease (CKD) were a central theme at the 2024 American Society of Nephrology (ASN) Kidney Week. Clinical studies reaffirmed the cardio-renal benefits of SGLT2i in CKD patients, including those with advanced-stage disease and elderly populations. Notably, these benefits persisted for up to 12 months after treatment discontinuation. Furthermore, CKD management has evolved from a traditional "three-pillar" approach to a "four-pillar" strategy, with combination therapies demonstrating significant synergistic potential for cardio-renal protection. Mechanistic studies revealed novel pathways through which SGLT2i exert renoprotective effects, including promoting renal regeneration, modulating epigenetic modifications, regulating immune cell activity, and restoring proximal tubule metabolic homeostasis. Further research is warranted to optimize therapeutic outcomes and maximize clinical benefits for patients.
